Resistant Hypertension and Related Outcomes in a Cohort of Patients with Cardiorenal Multimorbidity Hospitalized in an Internal Medicine Ward.
Cardiorenal multimorbidity
Chronic kidney disease
Heart failure
Resistant hypertension
Journal
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
ISSN: 1179-1985
Titre abrégé: High Blood Press Cardiovasc Prev
Pays: New Zealand
ID NLM: 9421087
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
14
10
2023
accepted:
13
11
2023
medline:
27
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
Resistant hypertension (RH) is characterized by the failure to reach a goal blood pressure despite the administration of three medications at maximally tolerated doses, one of which being a diuretic. RH can be observed in a variety of clinical conditions, such as heart failure and reduced renal function and may confer high cardiovascular risk. To evaluate the prevalence of RH and its association with clinical outcomes; the primary outcome was in-hospital mortality and the composite outcome was all-cause of mortality and morbidity in a cohort of patients with cardiorenal multimorbidity hospitalized in an internal medicine ward. We conducted a retrospective analysis of consecutive hypertensive patients with cardiorenal multimorbidity. The composite outcome incorporated all-cause of in-hospital mortality and occurrence of sepsis, pulmonary embolism, acute coronary syndrome, stroke and renal replacement therapy. We collected data in 141 inpatients with a mean age of 77 years ± 10 (males 65.9 %), estimated glomerular filtration rate of 34 ± 18.6 ml/min with length of stay of 17 ± 12 days. The prevalence of RH was 52.4%. In-hospital mortality was observed in 24 patients (17%) and the composite outcome occurred in 87 patients (61.7%) and among these 74 (85.1%) were patients with RH. Free survival for composite outcome was significantly higher in patients without RH than patients with RH (log rank 7.52, p = 0.006). Resistant hypertension was a risk factor for composite outcome [HR 1.857(C.I. 1.170-2.946, p = 0.009)]. In patients with cardiorenal multimorbidity there is a high proportion of RH that represents a risk factor for composite outcome but not for in-hospital mortality.
Identifiants
pubmed: 38010537
doi: 10.1007/s40292-023-00609-x
pii: 10.1007/s40292-023-00609-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023. https://doi.org/10.1097/HJH.0000000000003480 .
doi: 10.1097/HJH.0000000000003480
pubmed: 37850964
pmcid: 10399952
Romano S, Rigon G, Albrigi M, Tebaldi G, Sartorio A, Cristin L, Burrei G, Fava C, Minuz P. Hypertension, uncontrolled hypertension and resistant hypertension: prevalence, comorbidities and prescribed medications in 228,406 adults resident in urban areas. A population-based observational study. Intern Emerg Med. 2023;18(7):1951–9. https://doi.org/10.1007/s11739-023-03376-8 .
doi: 10.1007/s11739-023-03376-8
pubmed: 37530942
pmcid: 10543802
Romano S, Idolazzi C, Fava C, Fondrieschi L, Celebrano M, Delva P, Branz L, Donato A, Dalbeni A, Minuz P. Prevalence and comorbidities of resistant hypertension: a collaborative population-based observational study. High Blood Press Cardiovasc Prev. 2018;25(3):295–301. https://doi.org/10.1007/s40292-018-0268-x .
doi: 10.1007/s40292-018-0268-x
pubmed: 29959696
Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98–105. https://doi.org/10.1136/heartjnl-2018-313599 .
doi: 10.1136/heartjnl-2018-313599
pubmed: 30087099
de Souza F, Muxfeldt ES, Salles GF. Prognostic factors in resistant hypertension: implications for cardiovascular risk stratification and therapeutic management. Expert Rev Cardiovasc Ther. 2012;10(6):735–45. https://doi.org/10.1586/erc.12.58 .
doi: 10.1586/erc.12.58
pubmed: 22894630
Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168(21):2340–6. https://doi.org/10.1001/archinte.168.21.2340 .
doi: 10.1001/archinte.168.21.2340
pubmed: 19029499
Leontsinis I, Farmakis D, Avramidis D, Andrikou E, Valatsou A, Gartzonikas E, et al. Cardiorenal multimorbidity in hospitalized cardiology patients: the Hellenic Cardiorenal Morbidity Snapshot (HECMOS) study. Hellenic J Cardiol. 2023. https://doi.org/10.1016/j.hjc.2023.03.006 .
doi: 10.1016/j.hjc.2023.03.006
pubmed: 37146905
Chapter 1: definition and classification of CKD. Kidney Int Suppl (2011). 2013. https://doi.org/10.1038/kisup.2012.64 .
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 .
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):197–215. https://doi.org/10.1016/j.jacc.2021.09.005 .
doi: 10.1016/j.jacc.2021.09.005
pubmed: 34895951
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368 .
doi: 10.1093/eurheartj/ehab368
pubmed: 34447992
Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, Cooper-Dehoff RM. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635–43. https://doi.org/10.1097/HJH.0000000000000051 .
doi: 10.1097/HJH.0000000000000051
pubmed: 24299915
pmcid: 4118668
Lamirault G, Artifoni M, Daniel M, Barber-Chamoux N. Nantes University Hospital Working Group On Hypertension. Resistant Hypertension: Novel Insights. Curr Hypertens Rev. 2020;16(1):61–72. https://doi.org/10.2174/1573402115666191011111402 .
doi: 10.2174/1573402115666191011111402
pubmed: 31622203
Sim JJ, Bhandari SK, Shi J, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88(3):622–32. https://doi.org/10.1038/ki.2015.142 .
doi: 10.1038/ki.2015.142
pubmed: 25945406
pmcid: 4556588
Sarafidis PA, Georgianos PI, Zebekakis PE. Comparative epidemiology of resistant hypertension in chronic kidney disease and the general hypertensive population. Semin Nephrol. 2014;34(5):483–91. https://doi.org/10.1016/j.semnephrol.2014.08.001 .
doi: 10.1016/j.semnephrol.2014.08.001
pubmed: 25416656
Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013;8(9):1583–90. https://doi.org/10.2215/CJN.00550113 .
doi: 10.2215/CJN.00550113
pubmed: 23868902
pmcid: 3805064
Jin CN, Liu M, Sun JP, Fang F, Wen YN, Yu CM, Lee AP. The prevalence and prognosis of resistant hypertension in patients with heart failure. PLoS ONE. 2014;9(12): e114958. https://doi.org/10.1371/journal.pone.0114958 .
doi: 10.1371/journal.pone.0114958
pubmed: 25490405
pmcid: 4260939
Zhu B, Liu Y, Zhou W, Du Y, Qi D, Wang C, Cheng Q, Zhang Y, Wang S, Gao C. Clinical characteristics and outcomes of Chinese patients with coronary heart disease and resistant hypertension. J Clin Hypertens (Greenwich). 2023;25(4):350–9. https://doi.org/10.1111/jch.14651 .
doi: 10.1111/jch.14651
pubmed: 36929173
McCullough PA, Amin A, Pantalone KM, Ronco C. Cardiorenal Nexus: a review with focus on combined chronic heart and kidney failure, and insights from recent clinical trials. J Am Heart Assoc. 2022;11(11): e024139. https://doi.org/10.1161/JAHA.121.024139 .
doi: 10.1161/JAHA.121.024139
pubmed: 35616212
pmcid: 9238695
McCallum W, Sarnak MJ. Cardiorenal syndrome in the hospital. Clin J Am Soc Nephrol. 2023;18(7):933–45. https://doi.org/10.2215/CJN.0000000000000064 .
doi: 10.2215/CJN.0000000000000064
pubmed: 36787124
Muxfeldt ES, de Souza F, Margallo VS, Salles GF. Cardiovascular and renal complications in patients with resistant hypertension. Curr Hypertens Rep. 2014;16(9):471. https://doi.org/10.1007/s11906-014-0471-7 .
doi: 10.1007/s11906-014-0471-7
pubmed: 25079852
Di Pilla M, Bruno RM, Taddei S. Resistant hypertension: an incurable disease or just a challenge for our medical skill? High Blood Press Cardiovasc Prev. 2016;23(4):347–53. https://doi.org/10.1007/s40292-016-0159-y .
doi: 10.1007/s40292-016-0159-y
pubmed: 27188195
Schmieder RE, Mahfoud F, Mancia G, Azizi M, Böhm M, Dimitriadis K, Kario K, Kroon AA, Lobo DM, Ott C, Pathak A, Persu A, Scalise F, Schlaich M, Kreutz R, Tsioufis C, Members of the ESH Working Group on Device-Based Treatment of Hypertension. European Society of Hypertension position paper on renal denervation 021. J Hypertens. 2021;39(9):1733–41. https://doi.org/10.1097/HJH.0000000000002933 .
doi: 10.1097/HJH.0000000000002933
pubmed: 34261957
Barbato E, Azizi M, Schmieder RE, Lauder L, Bohm M, Brouwers S, et al. Renal Denervation in the Management of Hypertension in Adults. A Clinical Consensus Statement of the ESC Council on Hypertension and the European Association of Cardiovascular Interventions (EAPCI). Eur Heart J. 2023;44:1313–30.
doi: 10.1093/eurheartj/ehad054
pubmed: 36790101
Mahfoud F, Mancia G, Schmieder RE, Ruilope L, Narkiewicz K, Schlaich M, et al. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol. 2022;80:1871–80. https://doi.org/10.1016/j.jacc.2022.08.802 .
doi: 10.1016/j.jacc.2022.08.802
pubmed: 36357087
Dassanayake S, Sole G, Wilkins G, Gray E, Skinner M. Effectiveness of physical activity and exercise on ambulatory blood pressure in adults with resistant hypertension: a systematic review and meta-analysis. High Blood Press Cardiovasc Prev. 2022;29:275–86. https://doi.org/10.1007/s40292-022-00517-6 .
doi: 10.1007/s40292-022-00517-6
pubmed: 35366216
pmcid: 9050776